SCHEMBL4428735

SCHEMBL4428735

NC(=O)CNC(=O)c1ccc(OCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc1F

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PARP15 Q460N3 1/20 0.45
PARP10 Q53GL7 1/20 0.45
SPHK2 Q9NRA0 1/20 0.45
MRGPRX4 Q96LA9 2/20 0.45
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MAOB P27338 5/20 0.44
TACR1 P25103 6/20 0.43
CACNA1F O60840 2/20 0.43
CACNA1D Q01668 2/20 0.43
CACNA1S Q13698 2/20 0.43
CACNA1C Q13936 2/20 0.43
MAOA P21397 1/20 0.42
GPR119 Q8TDV5 1/20 0.42
TLR8 Q9NR97 1/20 0.42
HIF1A Q16665 1/20 0.41
PPARD Q03181 1/20 0.41
PPARA Q07869 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3651957 0.89 PARP15 (0.43) PARP15PARP10MRGPRX4MAPTHTT
SCHEMBL3505966 0.84 MAOB (0.63) PARP15PARP10SPHK2MAPTL3MBTL1
SCHEMBL4429301 0.84 SPHK2 (0.63) PARP15PARP10SPHK2MAOBMAOA
SCHEMBL4421346 0.82 MRGPRX4 (0.56) PARP15PARP10MRGPRX4MAPTHTT
SCHEMBL3502977 0.82 MAOB (0.46) PARP15PARP10MRGPRX4MAPTHTT
SCHEMBL3502975 0.82 MAOB (0.46) PARP15PARP10MRGPRX4MAPTHTT
SCHEMBL3506405 0.81 MAOB (0.65) PARP15PARP10SPHK2MAOBMAOA
SCHEMBL6470900 0.81 MAOB (0.51) PARP15PARP10SPHK2MAOBMAOA
SCHEMBL4428730 0.78 MAPT (0.47) PARP15PARP10MRGPRX4MAPTHTT
SCHEMBL4340548 0.76 MAOB (0.45) MRGPRX4MAPTHTTL3MBTL1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6951884-B2 Fluorobenzamides and uses thereof HOFFMANN-LA ROCHE INC. (US) 2005-10-04 US claimed
US-20030236304-A1 Fluorobenzamides and uses thereof F. HOFFMANN-LA ROCHE AG (CH) 2003-12-25 US claimed
EP-1515926-B1 FLUOROBENZAMIDES SUITABLE FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR SENILE DEMENTIA HOFFMANN LA ROCHE (CH) 2009-04-08 EP disclosed
CN-1274669-C Fluorobenzamides suitable for the treatment of alzheimer's disease or senile dementia HOFFMANN LA ROCHE (CH) 2006-09-13 CN disclosed
US-6951884-B2 Fluorobenzamides and uses thereof HOFFMANN-LA ROCHE INC. (US) 2005-10-04 US disclosed
CN-1659135-A Fluorobenzamides suitable for the treatment of alzheimer's disease or senile dementia HOFFMANN LA ROCHE (CH) 2005-08-24 CN disclosed
EP-1515926-A2 FLUOROBENZAMIDES SUITABLE FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR SENILE DEMENTIA F.HOFFMANN-LA ROCHE AG (CH) 2005-03-23 EP disclosed
US-20030236304-A1 Fluorobenzamides and uses thereof F. HOFFMANN-LA ROCHE AG (CH) 2003-12-25 US disclosed
WO-2003106380-A2 FLUOROBENZAMIDES F.HOFFMANN-LA ROCHE AG (CH) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236304-A1 Fluorobenzamides and uses thereof MAOB, MAOA, BCHE PARP15 806/4885PARP10 1686/4885SPHK2 2586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.